PDCD1 and melanoma: By using melanoma patients’ tissue samples collected before and during anti-PD-1 treatment (pembrolizumab), it was demonstrated that a higher frequency of pre-existing intratumoral CD8+ T-cells correlated with clinical responsiveness to anti-PD-1 therapy, in terms of radiographic reduction of the tumor size [27].